Loading…
Lobbying Income
$1.2M
Filings
39
Unique Clients
3
Active Period
2019–2024
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Saving Access to Laboratory Services Act
2023 · fourth_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
S.1000 - Saving Access to Laboratory Services Act which ensures access for Medicare beneficiaries to lab testing. FDA regulation of laboratory developed tests
Client expense: — · Firm income: $25,000
Matched citations: S.1000
Saving Access to Laboratory Services Act
2023 · third_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
S.1000 - Saving Access to Laboratory Services Act which ensures access for Medicare beneficiaries to lab testing. FDA regulation of laboratory developed tests
Client expense: — · Firm income: $25,000
Matched citations: S.1000
Saving Access to Laboratory Services Act
2023 · second_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
S.1000 - Saving Access to Laboratory Services Act which ensures access for Medicare beneficiaries to lab testing. FDA regulation of laboratory developed tests
Client expense: — · Firm income: $25,000
Matched citations: S.1000
Saving Access to Laboratory Services Act
2023 · first_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
S.1000 - Saving Access to Laboratory Services Act which ensures access for Medicare beneficiaries to lab testing.
Client expense: — · Firm income: $25,000
Matched citations: S.1000
Improving Seniors’ Timely Access to Care Act of 2019
2020 · fourth_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Issues involving diagnostic testing in responding to the Coronavirus pandemic
Client expense: — · Firm income: $50,000
Matched citations: HR 3107
Improving Seniors’ Timely Access to Care Act of 2019
2020 · third_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Issues involving diagnostic testing in responding to the Coronavirus pandemic
Client expense: — · Firm income: $60,000
Matched citations: HR 3107
Improving Seniors’ Timely Access to Care Act of 2019
2020 · second_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Issues involving diagnostic testing in responding to the Coronavirus pandemic
Client expense: — · Firm income: $50,000
Matched citations: HR 3107
Improving Seniors’ Timely Access to Care Act of 2019
2020 · first_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Issues involving diagnostic testing in responding to the Coronavirus pandemic
Client expense: — · Firm income: $50,000
Matched citations: HR 3107
Improving Seniors’ Timely Access to Care Act of 2019
2019 · fourth_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Payment for clinical lab testing/PAMA
Client expense: — · Firm income: $50,000
Matched citations: HR 3107
Improving Seniors’ Timely Access to Care Act of 2019
2019 · third_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Payment for clinical lab testing/PAMA
Client expense: — · Firm income: $51,000
Matched citations: HR 3107
Improving Seniors’ Timely Access to Care Act of 2019
2019 · second_quarter · Client: BIOREFERENCE LABORATORIES AN OPKO HEALTH COMPANY
HR 3107-Prior authorization for payment for genetic testing Regulation of clinical laboratory testing Payment for clinical lab testing/PAMA
Client expense: — · Firm income: $37,000
Matched citations: HR 3107
Source: Senate LDA